Rick Gonzalez, AP Images
March 30, 2021 09:42 AM EDT
Pharma

The IBD mar­ket is set to soar to $32B. Ab­b­Vie could be the big win­ner, but there's meat left on the bone — top an­a­lyst

Kyle Blankenship

Ab­b­Vie has pinned much of its hopes in a post-Al­ler­gan merg­er fu­ture on re­cent im­munol­o­gy launch­es Skyrizi and Rin­voq, which are ex­pect­ed to off­set the …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Sofinno­va out­lines $550M fund af­ter IPOs and M&A deals

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times